UK Accepts All 44 NHS AI Commission Recommendations, Sets December 2026 Deadline

What happened

Why it matters

• ·Compliance programs built around one-time device approval will not satisfy the new framework. Organizations selling AI-enabled medical devices into the UK market should begin mapping how their change management and post-market surveillance processes align with the December 2026 MHRA draft guidance.
• ·The MHRA AI Airlock Phase 3 sandbox creates a concrete opportunity for early regulatory engagement. Companies that participate can help shape practical standards and demonstrate proactive compliance, which is increasingly a factor in both procurement decisions and regulatory goodwill.
• ·Health sector procurement teams face a vendor due diligence gap: AI medical devices approved under current rules may not meet lifecycle governance requirements as new standards take effect. Contracts signed now should include provisions for ongoing conformance assessment and change notification obligations.

Governance controls affected

What to do now

• ☐Identify every AI-enabled medical device in your product portfolio or procurement pipeline that is sold or used in the UK, and flag each for review against the incoming lifecycle-based framework.
• ☐Review current change management documentation for AI medical devices to determine whether it captures the type of continuous monitoring and post-market evidence the MHRA December 2026 draft guidance is likely to require.
• ☐Ask your regulatory affairs and procurement teams whether supplier contracts for AI medical devices include obligations for vendors to notify you of material updates or retraining events that could affect device behavior.
• ☐Assess whether your organization should apply for AI Airlock Phase 3 to engage directly with MHRA on post-market surveillance standards before they are finalized.
• ☐Set a calendar trigger for December 2026 to review the draft MHRA guidance on AI device change management and assess any gap between current practices and the new requirements.

What to watch next

Compliance teams should monitor the MHRA's publication of draft AI device change management guidance, expected by December 2026, and the full implementation roadmap due Spring 2027. The AI Airlock Phase 3 application window is open now, and companies that miss it will have less influence over the practical standards that emerge. More broadly, this development is part of a wider pattern of regulators moving from static approvals to continuous oversight of AI systems in regulated sectors. Teams should watch for the EU AI Act to develop analogous requirements for high-risk medical AI under its own conformity assessment and post-market monitoring obligations.